Black Hawk Acquisition Corporation (BKHA)
BKHA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | BKHA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0002000775 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
Financials
Blank-check company: no operating revenue.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "In connection with the Company's assessment of going concern considerations in accordance with Financial Accounting Standard Board's Accounting Standards Update ( ASU ) 2014-15, Disclosures of Uncertainties about an Entity's Ability to Continue as a Going Concern, management has determined that these conditions raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-10-06 |
| Cash and burn | $0 cash; operating cash flow -$140K a quarter. | Report 2026-08-31 |
| Shares outstanding | 4,153,577 (2026-10-06); 4,153,577 a year earlier. | Cover page 2026-10-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-04-01 |
| Auditor | MaloneBailey, LLP, Houston, Texas, United States | PCAOB Form AP 2026-03-16 |
| Late filings, 12 months | 2 NT notices | NT 10-Q 2026-04-14 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-08-31 | Not filed | $1.1M | -$113K | $0 | $1.5M | Needs four quarters | 10-Q 2026-10-06 |
| Q2 2026 2026-05-31 | Not filed | $89K | -$237K | $0 | $1.2M | Needs four quarters | 10-Q 2026-07-15 |
| Q1 2026 2026-02-28 | Not filed | $140K | -$110K | $0 | $997K | Needs four quarters | 10-Q 2026-04-21 |
| Q4 2025 2025-11-30 | Not filed | -$4K | -$100K | $0 | $595K | Needs four quarters | 10-K 2026-03-06 |
| Q3 2025 2025-08-31 | Not filed | $154K | -$108K | $0 | $350K | Needs four quarters | 10-Q 2026-10-06 |
| Q2 2025 2025-05-31 | Not filed | $521K | -$279K | $0 | No debt tags | Needs four quarters | 10-Q 2026-07-15 |
| Q1 2025 2025-02-28 | Not filed | $658K | -$163K | $0 | No debt tags | Needs four quarters | 10-Q 2026-04-21 |
| Q4 2024 2024-11-30 | Not filed | $752K | -$59K | $0 | $0 | Needs four quarters | 10-K 2026-03-06 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2026-09-22 |
| Latest annual report | 10-K/A | 2026-04-28 |
| Latest quarterly / interim | 10-Q | 2026-10-06 |
| Latest current report | 8-K | 2026-10-23 |
| Latest proxy | DEFA14A | 2025-07-08 |
Source: SEC EDGAR submissions feed, 120 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +29.7% |
| 1 month | -41.5% |
| 3 months | -38.0% |
| Year to date | -35.1% |
| 1 year | -34.8% |
| From 52-week high | -44.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| BKHAR | Black Hawk Acquisition Corporation Rights | $1.39 |
| BKHAU | Black Hawk Acquisition Corporation Units | $7.26 |
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ODTX | Odyssey Therapeutics Inc. | $19.36 | +1.15% | $930.6M |
| IMTX | Immatics N.V. | $6.17 | -3.44% | $923.2M |
| INBX | Inhibrx Biosciences Inc. | $77.66 | -6.77% | $1.1B |
| VOR | Vor Biopharma Inc. | $18.97 | -2.32% | $1.2B |
| MGTX | MeiraGTx Holdings plc | $8.74 | -4.79% | $854.2M |
| GLUE | Monte Rosa Therapeutics Inc. | $9.16 | -2.24% | $782.7M |
| PRME | Prime Medicine Inc. | $4.19 | -1.87% | $762.3M |
| TSHA | Taysha Gene Therapies Inc. | $4.06 | -0.98% | $1.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier